Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.07. | C4 Therapeutics, Inc.: C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 | 3 | GlobeNewswire (USA) | ||
08.07. | C4 Therapeutics, Inc.: C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day | 4 | GlobeNewswire (USA) | ||
30.06. | C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? | 2 | Insider Monkey | ||
21.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.06. | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors | 2 | GlobeNewswire (USA) | ||
09.05. | Key Takeaways From C4 Therapeutics Analyst Ratings | 4 | Benzinga.com | ||
08.05. | C4 Therapeutics GAAP EPS of -$0.41 in-line, revenue of $3.04M misses by $6.24M | 3 | Seeking Alpha | ||
08.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
08.05. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
29.04. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 235 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
09.04. | C4 Therapeutics, Inc.: C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum | 2 | GlobeNewswire (USA) | ||
08.04. | C4 Therapeutics, Inc.: C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Me | 109 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
06.03. | Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m | 18 | PMLiVE | ||
04.03. | US STOCKS Avidity, C4 Therapeutics, Avadel Pharma | 3 | Reuters | ||
04.03. | C4 Therapeutics rises on license agreement with Merck KGaA | 7 | Reuters | ||
04.03. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins | 340 | GlobeNewswire (Europe) | Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research... ► Artikel lesen | |
27.02. | UBS cuts C4 Therapeutics stock target to $18, maintains Buy | 7 | Investing.com | ||
22.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 67,85 | +0,07 % | Schock-News für Morphosys Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
MODERNA | 111,52 | +0,13 % | Verlustreicher Tag für Moderna-Aktionäre: Aktienkurs sinkt deutlich (107,7255 €) | Zu den großen Verlierern an der Börse zählt am Mittwoch die Moderna-Aktie . Das Wertpapier verbilligt sich heute deutlich. Mit einem Minus von 3,55 Prozent gehört heute das Wertpapier von Moderna zu... ► Artikel lesen | |
VALNEVA | 3,292 | +0,12 % | Valneva-Aktie +6%: Das bringt neuen Schwung | Nach einer scharfen Korrektur am Freitag springt die Valneva-Aktie (WKN: A0MVJZ) am Montagmorgen um knapp +6% auf 3,48€. Eine bedeutende Finanzspritze sorgt für neue Impulse. Kann der Biotech-Titel... ► Artikel lesen | |
NOVAVAX | 15,736 | -0,18 % | Market Whales and Their Recent Bets on NVAX Options | ||
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,75 | -1,40 % | Is a Beat in the Cards for CRISPR Therapeutics (CRSP) in Q2 Earnings? | ||
INOVIO PHARMACEUTICALS | 10,280 | -1,34 % | INOVIO Pharmaceuticals, Inc.: Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 | Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,825 | +4,02 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate | Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today... ► Artikel lesen | |
INFLARX | 1,417 | +1,50 % | InflaRx N.V.: InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) | JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign | ||
INTELLIA THERAPEUTICS | 24,570 | +0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
VIVORYON THERAPEUTICS | 2,385 | -1,45 % | Vivoryon mit Neuausrichtung: Aktie legt weiter zu - das ist geplant | Die Aktie des früheren Alzheimer-Hoffnungsträgers Vivoryon hat zuletzt erneut zulegen können. Das deutsche Biotech-Unternehmen arbeitet derzeit an einer strategischen Neuausrichtung. Zukünftig will... ► Artikel lesen | |
EDITAS MEDICINE | 5,322 | +2,35 % | Editas Medicine, Inc.: Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress | All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was... ► Artikel lesen | |
VIKING THERAPEUTICS | 60,42 | -0,53 % | Adipositas-Hoffnung Viking Therapeutics: Aktie mit 24-Prozent-Kurssprung - was ist da los? | Die Aktie des US-Biotech-Unternehmens Viking Therapeutics hat am Mittwoch nach US-Börsenschluss einen kräftigen Kurssprung von 24 Prozent hinlegen können. Das Unternehmen, das insbesondere als großer... ► Artikel lesen |